2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
Aug 9, 2018
Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results
Aug 8, 2018
Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference
Jul 31, 2018
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease
Jun 19, 2018
Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan
May 10, 2018
Kala Pharmaceuticals Reports First Quarter 2018 Financial Results
May 9, 2018
Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch
May 8, 2018
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
Apr 9, 2018
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Apr 9, 2018
Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS
Apr 3, 2018
Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary
Mar 26, 2018
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 19, 2018
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call
Mar 14, 2018
Kala Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
Mar 5, 2018
Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair
Jan 5, 2018
Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease
Jan 5, 2018
Kala Pharmaceuticals Announces New Drug Application for INVELTYS™ (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration